The global cell and gene therapy market size was USD 18.12 billion in 2023, calculated at USD 21.28 billion in 2024 and is expected to reach around USD 117.46 billion by 2034, expanding at a CAGR of 18.6% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell and Gene Therapy Market
5.1. COVID-19 Landscape: Cell and Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell and Gene Therapy Market, By Therapy Type
8.1. Cell and Gene Therapy Market, by Therapy Type, 2024-2034
8.1.1. Cell Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Gene Therapy
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Cell and Gene Therapy Market, By Therapeutic class
9.1. Cell and Gene Therapy Market, by Therapeutic class, 2024-2034
9.1.1. Cardiovascular Disease
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Genetic Disorder
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Rare Diseases
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Oncology
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Oncology
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Ophthalmology
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Infectious Disease
9.1.8.1. Market Revenue and Forecast (2021-2034)
9.1.9. Neurological Disorders
9.1.9.1. Market Revenue and Forecast (2021-2034)
9.1.10. Others
9.1. 10.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Cell and Gene Therapy Market, By Delivery Method
10.1. Cell and Gene Therapy Market, by Delivery Method, 2024-2034
10.1.1. In Vivo
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Ex vivo
10.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Cell and Gene Therapy Market, By End-Users
11.1. Cell and Gene Therapy Market, by End-Users, 2024-2034
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Cancer Care Centers
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Cell and Gene Therapy Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.1.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.1.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.2.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.2.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.3.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.3.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.4.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.4.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.5.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Therapeutic class (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Delivery Method (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
Chapter 13. Company Profiles
13.1. Alnylam Pharmaceuticals Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amgen Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Biogen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. CORESTEM Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Dendreon Pharmaceuticals LLC.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Helixmith Co. Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. JCR Pharmaceuticals Co. Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Kolon TissueGene Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis AG
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample